Adverse events reported after the use of recombinant human bone morphogenetic protein 2.


Abstract

Serious adverse events, some of which may require a second operation, can occur after the use of rhBMP-2 in oral and maxillofacial procedures.

In this analysis graft, failure and pseudarthrosis were more commonly reported after off-label uses of rhBMP-2 than approved uses.


Full Text


Subjects


Similar articles

Español | English

© Galenicom 1999-2013